N
21.99
1.25 (6.03%)
| Previous Close | 20.74 |
| Open | 20.09 |
| Volume | 193,861 |
| Avg. Volume (3M) | 173,563 |
| Market Cap | 340,620,704 |
| Price / Sales | 438.73 |
| Price / Book | 1.26 |
| 52 Weeks Range | |
| Earnings Date | 23 Mar 2026 |
| Operating Margin (TTM) | -9,701.19% |
| Diluted EPS (TTM) | -4.36 |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 21.03 |
| Operating Cash Flow (TTM) | -69.73 M |
| Levered Free Cash Flow (TTM) | -40.39 M |
| Return on Assets (TTM) | -21.97% |
| Return on Equity (TTM) | -34.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Neurogene Inc. | Mixed | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.28% |
| % Held by Institutions | 115.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trails Edge Capital Partners, Lp | 31 Dec 2025 | 785,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (Canaccord Genuity, 809.50%) | Buy |
| Median | 70.00 (218.33%) | |
| Low | 50.00 (LifeSci Capital, 127.38%) | Buy |
| Average | 106.67 (385.08%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 19.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 27 Feb 2026 | 200.00 (809.50%) | Buy | 23.49 |
| LifeSci Capital | 26 Jan 2026 | 50.00 (127.38%) | Buy | 19.12 |
| HC Wainwright & Co. | 13 Jan 2026 | 70.00 (218.33%) | Buy | 16.95 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome |
| 05 Jan 2026 | Announcement | Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |